N-Acetyl Cysteine (Nac) for Respiratory Health

Research suggests that N-acetyl cysteine (NAC) may play a supportive role in respiratory health, particularly in the context of viral infections like COVID-19, primarily through its antioxidant properties and ability to reduce oxidative stress and inflammation in airway cells. Laboratory and animal studies indicate that NAC can suppress SARS-CoV-2 replication across multiple variants by targeting reactive oxygen species produced early in the viral replication cycle, and related thiol compounds have shown some ability to reduce lung inflammation in animal models, though effects on viral load itself were limited. Clinical evidence comes largely from small observational studies and early-phase trials rather than large randomized controlled trials, including a retrospective case series and a phase 2/3 trial examining NAC as part of a broader combination therapy, both of which reported faster recovery or lower mortality — findings that are difficult to attribute specifically to NAC given the multi-drug designs and lack of robust control groups. Overall, the body of evidence is preliminary and largely indirect, with mechanistic findings from cell and animal studies not yet fully validated in well-controlled human trials, meaning conclusions about NAC's respiratory benefits should be interpreted cautiously.